FDA Accepts Filing of NDA for GeNOsyl MVG-2000 Nitric Oxide Delivery System

Share this article:

GeNO LLC announced that its New Drug Application (NDA) for the GeNOsyl MVG-2000 Nitric Oxide Delivery System for neonates with hypoxic respiratory failure has been accepted for filing by the FDA.

GeNOsyl nitric oxide for inhalation is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is used for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

For more information visit www.genollc.com.

Share this article:

Related Resources

close

Next Article in Drugs in the Pipeline